Drug Trial Radar · NCT07318558
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Feb 16, 2026
Primary completion
Feb 25, 2033
Study completion Feb 25, 2033
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Conditions
- Ovarian Neoplasms
- Ovarian Cancer
Interventions
Sacituzumab tirumotecanDrug
Administered via intravenous (IV) infusion at a dose of 4mg/kg
BevacizumabDrug
Administered via IV infusion at a dose of 15mg/kg
Rescue MedicationsDrug
Participants must receive prophylactic steroid mouthwash (dexamethasone or equivalent). It is recommended that participants receive the following rescue medications prior to sac-TMT infusion, per approved product label: histamine-1 receptor antagonist, histamine-2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 49 months
Locations
178 sites in 30 countries. Site status is shown where the registry gives one.
University of Alabama - Birmingham ( Site 0058)
Birmingham, Alabama · Recruiting
UCSD Moores Cancer Center ( Site 0038)
La Jolla, California · Recruiting
Hoag Memorial Hospital Presbyterian ( Site 0074)
Newport Beach, California · Recruiting
John Muir Health Cancer Center ( Site 0069)
Walnut Creek, California · Recruiting
Anschutz Cancer Pavilion ( Site 0049)
Aurora, Colorado · Recruiting
University of Colorado Health - Highlands Ranch Hospital ( Site 0094)
Highlands Ranch, Colorado · Recruiting
Mount Sinai Cancer Center ( Site 0029)
Miami Beach, Florida · Recruiting
Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085)
Orlando, Florida · Recruiting
Winship Cancer Institute of Emory University ( Site 0037)
Atlanta, Georgia · Recruiting
Illinois Cancer Specialists (ICS) ( Site 8009)
Arlington Heights, Illinois · Recruiting
Parkview Research Center at Parkview Regional Medical Center ( Site 0055)
Fort Wayne, Indiana · Recruiting
Franciscan Health Indianapolis ( Site 0081)
Indianapolis, Indiana · Recruiting
Women's Cancer Care ( Site 0018)
Covington, Louisiana · Recruiting
Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0060)
Scarborough, Maine · Recruiting
Maryland Oncology Hematology (MOH) ( Site 8002)
Columbia, Maryland · Recruiting
Nebraska Methodist Hospital ( Site 0004)
Omaha, Nebraska · Recruiting
University Of Nebraska Medical Center ( Site 0035)
Omaha, Nebraska · Recruiting
The Center of Hope ( Site 0025)
Reno, Nevada · Recruiting
Womens Cancer Care Associates, LLC ( Site 0023)
Albany, New York · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 0072)
New York, New York · Recruiting
Duke Cancer Center ( Site 0012)
Durham, North Carolina · Recruiting
University of Cincinnati Medical Center ( Site 0042)
Cincinnati, Ohio · Recruiting
The Ohio State University ( Site 0005)
Hilliard, Ohio · Recruiting
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007)
Tulsa, Oklahoma · Recruiting
Kaiser Permanente Interstate Medical Office - Central ( Site 0089)
Portland, Oregon · Recruiting
Hospital of the University of Pennsylvania ( Site 0071)
Philadelphia, Pennsylvania · Recruiting
AHN West Penn Hospital ( Site 0051)
Pittsburgh, Pennsylvania · Recruiting
Women & Infants Hospital ( Site 0001)
Providence, Rhode Island · Recruiting
West Cancer Center and Research Institute ( Site 0013)
Germantown, Tennessee · Recruiting
University of Tennessee Medical Center ( Site 0087)
Knoxville, Tennessee · Recruiting
Henry-Joyce Cancer Clinic ( Site 0011)
Nashville, Tennessee · Recruiting
JPS Health Network ( Site 0084)
Fort Worth, Texas · Recruiting
Virginia Cancer Specialists (VCS) ( Site 8012)
Fairfax, Virginia · Recruiting
Virginia Oncology Associates (VOA) ( Site 8013)
Norfolk, Virginia · Recruiting
Hospital Britanico de Buenos Aires ( Site 2905)
CABA, Argentina · Recruiting
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 2907)
La Rioja, Argentina · Recruiting
Hospital Aleman ( Site 2903)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Instituto Alexander Fleming ( Site 2902)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Clinicas Mar del Plata ( Site 2901)
Mar del Plata, Buenos Aires, Argentina · Recruiting
Fundación Respirar ( Site 2912)
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Showing 40 of 178 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.